Several preclinical studies indicate that the anti-tumor efficacy of various T cell activating immunotherapies, such as mAbs to CTLA-4, PD-1, CD137, or CD40, vaccines and adoptive T cell transfer, can be enhanced by radiotherapy (e.g., [14, 16, 17, 22–24]. This evidence concerns the gene TNFRSF9 and neoplasm.